Peter Berger
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Peter Berger has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Natalie Sampson
Department of Urology, Medical University of Innsbruck, Innsbruck, Austria
7 shared publications Christoph Zenzmaier
Institute for Biomedical Aging Research, Austrian Academy of Sciences, A-6020 Innsbruck, Austria
5 shared publicationsGerold Untergasser
Laboratory of Tumor Biology and Angiogenesis, Department of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria
4 shared publications- Christoph Zenzmaier
Health University of Applied Sciences Tyrol, Innsbruck, Austria
3 shared publications Eugen Plas
Ludwig Boltzmann Institute for Andrology and Urology (E.P.), Hospital Lainz, A1130 Vienna, Austria
3 shared publicationsG Untergasser
Tumor Biology and Angiogenesis Laboratory, Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications
Latest Publications
- Open Access
- 22 October 2012
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2012, 1-15
Therapeutic Targeting of Redox Signaling in Myofibroblast Differentiation and Age-Related Fibrotic Disease
Myofibroblast activation plays a central role during normal wound healing. Whereas insufficient myofibroblast activation impairs wound healing, excessive myofibroblast activation promotes fibrosis in diverse tissues (including benign prostatic hyperplasia, BPH) leading to organ dysfunction and also promotes a stromal response that supports tumor progression. The incidence of impaired wound healing, tissue fibrosis, BPH, and certain cancers strongly increases with age. This paper summarizes findings fromin vitrofibroblast-to-myofibroblast differentiation systems that serve as cellular models to study fibrogenesis of diverse tissues. Supported by substantialin vivodata, a large body of evidence indicates that myofibroblast differentiation induced by the profibrotic cytokine transforming growth factor beta is driven by a prooxidant shift in redox homeostasis due to elevated production of NADPH oxidase 4 (NOX4)-derived hydrogen peroxide and supported by concomitant decreases in nitric oxide/cGMP signaling and reactive oxygen species (ROS) scavenging enzymes. Fibroblast-to-myofibroblast differentiation can be inhibited and reversed by restoring redox homeostasis using antioxidants or NOX4 inactivation as well as enhancing nitric oxide/cGMP signaling via activation of soluble guanylyl cyclases or inhibition of phosphodiesterases. Current evidence indicates the therapeutic potential of targeting the prooxidant shift in redox homeostasis for the treatment of age-related diseases associated with myofibroblast dysregulation.
- 22 October 2012
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2012, 1-15
Open AccessTherapeutic Targeting of Redox Signaling in Myofibroblast Differentiation and Age-Related Fibrotic Disease
Myofibroblast activation plays a central role during normal wound healing. Whereas insufficient myofibroblast activation impairs wound healing, excessive myofibroblast activation promotes fibrosis in diverse tissues (including benign prostatic hyperplasia, BPH) leading to organ dysfunction and also promotes a stromal response that supports tumor progression. The incidence of impaired wound healing, tissue fibrosis, BPH, and certain cancers strongly increases with age. This paper summarizes findings fromin vitrofibroblast-to-myofibroblast differentiation systems that serve as cellular models to study fibrogenesis of diverse tissues. Supported by substantialin vivodata, a large body of evidence indicates that myofibroblast differentiation induced by the profibrotic cytokine transforming growth factor beta is driven by a prooxidant shift in redox homeostasis due to elevated production of NADPH oxidase 4 (NOX4)-derived hydrogen peroxide and supported by concomitant decreases in nitric oxide/cGMP signaling and reactive oxygen species (ROS) scavenging enzymes. Fibroblast-to-myofibroblast differentiation can be inhibited and reversed by restoring redox homeostasis using antioxidants or NOX4 inactivation as well as enhancing nitric oxide/cGMP signaling via activation of soluble guanylyl cyclases or inhibition of phosphodiesterases. Current evidence indicates the therapeutic potential of targeting the prooxidant shift in redox homeostasis for the treatment of age-related diseases associated with myofibroblast dysregulation.
- 16 November 2011
- Published by CSIRO Publishing in Reproduction, Fertility and Development
- Vol. 24 (3) , 517-522
Seminal plasma enhances and accelerates progesterone-induced decidualisation of human endometrial stromal cells
In preparation for embryo implantation, endometrial stromal cells (ESC) undergo differentiation, termed decidualisation. Enhancing endometrial decidualisation may overcome reduced endometrial receptivity, a major limiting factor in natural and assisted reproduction. To determine whether seminal plasma (SP) influences decidualisation, primary human ESC were treated with progesterone (P4, 50 ng mL–1) in the presence or absence of dialysed SP (0.5%) for 24 h or for up to 27 days to investigate immediate early effects or the effects of prolonged exposure, respectively. Combined SP and P4 treatment induced ESC morphological differentiation. Relative to control, P4 alone, and SP alone combined treatment with SP and P4 for 27 days significantly upregulated mRNA levels of the decidua-specific markers prolactin (PRL) and insulin-like growth factor binding protein 1 (IGFBP1). Consistently, PRL protein secretion was significantly increased over the course of 27 days combined SP and P4 treatment relative to control, P4 alone and SP alone. Likewise, IGFBP1 secretion was significantly greater relative to control and P4 alone over the course of 27 days. Thus, SP enhances and accelerates P4-mediated decidualisation of human ESC and may enhance endometrial receptivity.
- 16 November 2011
- Published by CSIRO Publishing in Reproduction, Fertility and Development
- Vol. 24 (3) , 517-522
Seminal plasma enhances and accelerates progesterone-induced decidualisation of human endometrial stromal cells
In preparation for embryo implantation, endometrial stromal cells (ESC) undergo differentiation, termed decidualisation. Enhancing endometrial decidualisation may overcome reduced endometrial receptivity, a major limiting factor in natural and assisted reproduction. To determine whether seminal plasma (SP) influences decidualisation, primary human ESC were treated with progesterone (P4, 50 ng mL–1) in the presence or absence of dialysed SP (0.5%) for 24 h or for up to 27 days to investigate immediate early effects or the effects of prolonged exposure, respectively. Combined SP and P4 treatment induced ESC morphological differentiation. Relative to control, P4 alone, and SP alone combined treatment with SP and P4 for 27 days significantly upregulated mRNA levels of the decidua-specific markers prolactin (PRL) and insulin-like growth factor binding protein 1 (IGFBP1). Consistently, PRL protein secretion was significantly increased over the course of 27 days combined SP and P4 treatment relative to control, P4 alone and SP alone. Likewise, IGFBP1 secretion was significantly greater relative to control and P4 alone over the course of 27 days. Thus, SP enhances and accelerates P4-mediated decidualisation of human ESC and may enhance endometrial receptivity.
- Open Access
- 10 November 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 193
Elevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients
Expression of Dkk-3, a secreted putative tumor suppressor, is altered in age-related proliferative disorders of the human prostate. We now investigated the suitability of Dkk-3 as a diagnostic biomarker for prostate cancer (PCa) in seminal plasma (SP). SP samples were obtained from 81 patients prior to TRUS-guided prostate biopsies on the basis of elevated serum prostate-specific antigen (PSA; > 4 ng/mL) levels and/or abnormal digital rectal examination. A sensitive indirect immunoenzymometric assay for Dkk-3 was developed and characterized in detail. SP Dkk-3 and PSA levels were determined and normalized to total SP protein. The diagnostic accuracies of single markers including serum PSA and multivariate models to discriminate patients with positive (N = 40) and negative (N = 41) biopsy findings were investigated. Biopsy-confirmed PCa showed significantly higher SP Dkk-3 levels (100.9 ± 12.3 vs. 69.2 ± 9.4 fmol/mg; p = 0.026). Diagnostic accuracy (AUC) of SP Dkk-3 levels (0.633) was enhanced in multivariate models by including serum PSA (model A; AUC 0.658) or both, serum and SP PSA levels (model B; AUC 0.710). In a subpopulation with clinical follow-up > 3 years post-biopsy to ensure veracity of negative biopsy status (positive biopsy N = 21; negative biopsy N = 25) AUCs for SP Dkk-3, model A and B increased to 0.667, 0.724 and 0.777, respectively. In multivariate models to detect PCa, inclusion of SP Dkk-3 levels, which were significantly elevated in biopsy-confirmed PCa patients, improved the diagnostic performance compared with serum PSA only.
- 10 November 2011
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 9 (1) , 193
Open AccessElevated levels of Dickkopf-related protein 3 in seminal plasma of prostate cancer patients
Expression of Dkk-3, a secreted putative tumor suppressor, is altered in age-related proliferative disorders of the human prostate. We now investigated the suitability of Dkk-3 as a diagnostic biomarker for prostate cancer (PCa) in seminal plasma (SP). SP samples were obtained from 81 patients prior to TRUS-guided prostate biopsies on the basis of elevated serum prostate-specific antigen (PSA; > 4 ng/mL) levels and/or abnormal digital rectal examination. A sensitive indirect immunoenzymometric assay for Dkk-3 was developed and characterized in detail. SP Dkk-3 and PSA levels were determined and normalized to total SP protein. The diagnostic accuracies of single markers including serum PSA and multivariate models to discriminate patients with positive (N = 40) and negative (N = 41) biopsy findings were investigated. Biopsy-confirmed PCa showed significantly higher SP Dkk-3 levels (100.9 ± 12.3 vs. 69.2 ± 9.4 fmol/mg; p = 0.026). Diagnostic accuracy (AUC) of SP Dkk-3 levels (0.633) was enhanced in multivariate models by including serum PSA (model A; AUC 0.658) or both, serum and SP PSA levels (model B; AUC 0.710). In a subpopulation with clinical follow-up > 3 years post-biopsy to ensure veracity of negative biopsy status (positive biopsy N = 21; negative biopsy N = 25) AUCs for SP Dkk-3, model A and B increased to 0.667, 0.724 and 0.777, respectively. In multivariate models to detect PCa, inclusion of SP Dkk-3 levels, which were significantly elevated in biopsy-confirmed PCa patients, improved the diagnostic performance compared with serum PSA only.
- Open Access
- 29 August 2011
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 40 (1) , 40-46
Dickkopf-3 maintains the PANC-1 human pancreatic tumor cells in a dedifferentiated state
Pancreatic cancer (PaCa) is the fourth leading cause of cancer deaths in Western societies, with pancreatic ductal adenocarcinomas (PDACs) accounting for >90% of such cases. PDAC is a heterogeneous disease that includes a subset showing overexpression of the secreted glycoprotein Dickkopf-related protein 3 (Dkk-3), a protein shown to be downregulated in various cancers of different tissues. The biological function of Dkk-3 in this subset was studied using the Dkk-3 expressing PANC-1 cell line as a model for PDACs. The influence of Dkk-3 overexpression and knockdown on cellular differentiation and proliferation of PANC-1 was investigated. Confocal microscopy showed that Dkk-3 was expressed in a fraction of PANC-1 cells. While lentiviral-mediated overexpression of DKK3 did not alter cellular proliferation, knockdown of DKK3 resulted in significant reduction of cellular proliferation and concomitant induction of cell cycle inhibitors CDKN2B (p15INK4b), CDKN1A (p21CIP1) and CDKN1B (p27KIP1). In parallel, pancreatic epithelial cell differentiation markers AMY2A, CELA1, CTRB1, GCG, GLB1 and INS were significantly upregulated. PANC-1 cells differentiated using exendin-4 showed analogous induction of cell cycle inhibitors and differentiation markers. Thus, we conclude that Dkk-3 is required to maintain a highly dedifferentiated and consequently proliferative state in PANC-1, indicating a similar function in the Dkk-3 overexpressing subset of PDACs. Therefore, Dkk-3 represents a potential target for the treatment of Dkk-3-positive subtypes of PaCa to drive cells into cell cycle arrest and differentiation.
- 29 August 2011
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 40 (1) , 40-46
Open AccessDickkopf-3 maintains the PANC-1 human pancreatic tumor cells in a dedifferentiated state
Pancreatic cancer (PaCa) is the fourth leading cause of cancer deaths in Western societies, with pancreatic ductal adenocarcinomas (PDACs) accounting for >90% of such cases. PDAC is a heterogeneous disease that includes a subset showing overexpression of the secreted glycoprotein Dickkopf-related protein 3 (Dkk-3), a protein shown to be downregulated in various cancers of different tissues. The biological function of Dkk-3 in this subset was studied using the Dkk-3 expressing PANC-1 cell line as a model for PDACs. The influence of Dkk-3 overexpression and knockdown on cellular differentiation and proliferation of PANC-1 was investigated. Confocal microscopy showed that Dkk-3 was expressed in a fraction of PANC-1 cells. While lentiviral-mediated overexpression of DKK3 did not alter cellular proliferation, knockdown of DKK3 resulted in significant reduction of cellular proliferation and concomitant induction of cell cycle inhibitors CDKN2B (p15INK4b), CDKN1A (p21CIP1) and CDKN1B (p27KIP1). In parallel, pancreatic epithelial cell differentiation markers AMY2A, CELA1, CTRB1, GCG, GLB1 and INS were significantly upregulated. PANC-1 cells differentiated using exendin-4 showed analogous induction of cell cycle inhibitors and differentiation markers. Thus, we conclude that Dkk-3 is required to maintain a highly dedifferentiated and consequently proliferative state in PANC-1, indicating a similar function in the Dkk-3 overexpressing subset of PDACs. Therefore, Dkk-3 represents a potential target for the treatment of Dkk-3-positive subtypes of PaCa to drive cells into cell cycle arrest and differentiation.
- Open Access
- 12 August 2011
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 9 (1) , 114
Decreased levels of genuine large free hCG alpha in men presenting with abnormal semen analysis
Background: The pregnancy hormone human chorionic gonadotropin (hCG) and its free subunits (hCG alpha, hCG beta) are produced in the male reproductive tract and found in high concentrations in seminal fluid, in particular hCG alpha. This study aimed to elucidate changes in peptide hormone profiles in patients showing abnormal semen analyses and to determine the genuineness of the highly abundant hCG alpha. Methods: Seminal plasma was obtained from 45 male patients undergoing semen analysis during infertility workups. Comprehensive peptide hormone profiles were established by a panel of immunofluorometric assays for hCG, hCG alpha, hCG beta and its metabolite hCG beta core fragment, placental lactogen, growth hormone and prolactin in seminal plasma of patients with abnormal semen analysis results (n = 29) versus normozoospermic men (n = 16). The molecular identity of large hyperglycosylated hCG alpha was analyzed by mass-spectrometry and selective deglycosylation. Results: hCG alpha levels were found to be significantly lower in men with impaired semen quality (1346 +/- 191 vs. 2753 +/- 533 ng/ml, P = 0.022). Moreover, patients with reduced sperm count had reduced intact hCG levels compared with normozoospermic men (0.097 +/- 0.022 vs. 0.203 +/- 0.040 ng/ml, P = 0.028). Using mass-spectrometry, the biochemical identity of hCG alpha purified from seminal plasma was verified. Under non-reducing conditions in SDS-PAGE, hCG alpha isolated from seminal plasma migrated in a manner comparable with large free hCG alpha with an apparent molecular mass (Mr, app) of 24 kDa, while hCG alpha dissociated from pregnancy-derived holo-hCG migrated at approximately 22 kDa. After deglycosylation with PNGase F under denaturing conditions, all hCG alpha variants showed an Mr, app of 15 kDa, indicating identical amino acid backbones. Conclusions: The findings indicate a pathophysiological relevance of hCG, particularly its free alpha subunit, in spermatogenesis. The alternative glycosylation pattern on the free large hCG alpha in seminal plasma might reflect a modified function of this subunit in the male reproductive tract.
- 12 August 2011
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 9 (1) , 114
Open AccessDecreased levels of genuine large free hCG alpha in men presenting with abnormal semen analysis
Background: The pregnancy hormone human chorionic gonadotropin (hCG) and its free subunits (hCG alpha, hCG beta) are produced in the male reproductive tract and found in high concentrations in seminal fluid, in particular hCG alpha. This study aimed to elucidate changes in peptide hormone profiles in patients showing abnormal semen analyses and to determine the genuineness of the highly abundant hCG alpha. Methods: Seminal plasma was obtained from 45 male patients undergoing semen analysis during infertility workups. Comprehensive peptide hormone profiles were established by a panel of immunofluorometric assays for hCG, hCG alpha, hCG beta and its metabolite hCG beta core fragment, placental lactogen, growth hormone and prolactin in seminal plasma of patients with abnormal semen analysis results (n = 29) versus normozoospermic men (n = 16). The molecular identity of large hyperglycosylated hCG alpha was analyzed by mass-spectrometry and selective deglycosylation. Results: hCG alpha levels were found to be significantly lower in men with impaired semen quality (1346 +/- 191 vs. 2753 +/- 533 ng/ml, P = 0.022). Moreover, patients with reduced sperm count had reduced intact hCG levels compared with normozoospermic men (0.097 +/- 0.022 vs. 0.203 +/- 0.040 ng/ml, P = 0.028). Using mass-spectrometry, the biochemical identity of hCG alpha purified from seminal plasma was verified. Under non-reducing conditions in SDS-PAGE, hCG alpha isolated from seminal plasma migrated in a manner comparable with large free hCG alpha with an apparent molecular mass (Mr, app) of 24 kDa, while hCG alpha dissociated from pregnancy-derived holo-hCG migrated at approximately 22 kDa. After deglycosylation with PNGase F under denaturing conditions, all hCG alpha variants showed an Mr, app of 15 kDa, indicating identical amino acid backbones. Conclusions: The findings indicate a pathophysiological relevance of hCG, particularly its free alpha subunit, in spermatogenesis. The alternative glycosylation pattern on the free large hCG alpha in seminal plasma might reflect a modified function of this subunit in the male reproductive tract.
- 1 March 2011
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 25 (3) , 503-515
ROS Signaling by NOX4 Drives Fibroblast-to-Myofibroblast Differentiation in the Diseased Prostatic Stroma
Stromal remodeling, in particular fibroblast-to-myofibroblast differentiation, is a hallmark of benign prostatic hyperplasia (BPH) and solid tumors, including prostate cancer (PCa). Increased local production of TGFβ1 is considered the inducing stimulus. Given that stromal remodeling actively promotes BPH/PCa development, there is considerable interest in developing stromal-targeted therapies. Microarray and quantitative PCR analysis of primary human prostatic stromal cells induced to undergo fibroblast-to-myofibroblast differentiation with TGFβ1 revealed up-regulation of the reactive oxygen species (ROS) producer reduced nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) and down-regulation of the selenium-containing ROS-scavenging enzymes glutathione peroxidase 3, thioredoxin reductase 1 (TXNRD1), and the selenium transporter selenoprotein P plasma 1. Consistently, NOX4 expression correlated specifically with the myofibroblast phenotype in vivo, and loss of selenoprotein P plasma 1 was observed in tumor-associated stroma of human PCa biopsies. Using lentiviral NOX4 short hairpin RNA-mediated knockdown, pharmacological inhibitors, antioxidants, and selenium, we demonstrate that TGFβ1 induction of NOX4-derived ROS is required for TGFβ1-mediated phosphorylation of c-jun N-terminal kinase, which in turn is essential for subsequent downstream cytoskeletal remodeling. Significantly, selenium supplementation inhibited differentiation by increasing ROS-scavenging selenoenzyme biosynthesis because glutathione peroxidase 3 and TXNRD1 expression and TXNRD1 enzyme activity were restored. Consistently, selenium depleted ROS levels downstream of NOX4 induction. Collectively, this work demonstrates that dysregulated redox homeostasis driven by elevated NOX4-derived ROS signaling underlies fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Further, these data indicate the potential clinical value of selenium and/or NOX4 inhibitors in preventing the functional pathogenic changes of stromal cells in BPH and PCa.
- 1 March 2011
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 25 (3) , 503-515
ROS Signaling by NOX4 Drives Fibroblast-to-Myofibroblast Differentiation in the Diseased Prostatic Stroma
Stromal remodeling, in particular fibroblast-to-myofibroblast differentiation, is a hallmark of benign prostatic hyperplasia (BPH) and solid tumors, including prostate cancer (PCa). Increased local production of TGFβ1 is considered the inducing stimulus. Given that stromal remodeling actively promotes BPH/PCa development, there is considerable interest in developing stromal-targeted therapies. Microarray and quantitative PCR analysis of primary human prostatic stromal cells induced to undergo fibroblast-to-myofibroblast differentiation with TGFβ1 revealed up-regulation of the reactive oxygen species (ROS) producer reduced nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) and down-regulation of the selenium-containing ROS-scavenging enzymes glutathione peroxidase 3, thioredoxin reductase 1 (TXNRD1), and the selenium transporter selenoprotein P plasma 1. Consistently, NOX4 expression correlated specifically with the myofibroblast phenotype in vivo, and loss of selenoprotein P plasma 1 was observed in tumor-associated stroma of human PCa biopsies. Using lentiviral NOX4 short hairpin RNA-mediated knockdown, pharmacological inhibitors, antioxidants, and selenium, we demonstrate that TGFβ1 induction of NOX4-derived ROS is required for TGFβ1-mediated phosphorylation of c-jun N-terminal kinase, which in turn is essential for subsequent downstream cytoskeletal remodeling. Significantly, selenium supplementation inhibited differentiation by increasing ROS-scavenging selenoenzyme biosynthesis because glutathione peroxidase 3 and TXNRD1 expression and TXNRD1 enzyme activity were restored. Consistently, selenium depleted ROS levels downstream of NOX4 induction. Collectively, this work demonstrates that dysregulated redox homeostasis driven by elevated NOX4-derived ROS signaling underlies fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Further, these data indicate the potential clinical value of selenium and/or NOX4 inhibitors in preventing the functional pathogenic changes of stromal cells in BPH and PCa.
- Open Access
- 25 June 2009
- Published by Wiley in Journal of Neurochemistry
- Vol. 110 (2) , 653-661
Dkk‐3 is elevated in CSF and plasma of Alzheimer’s disease patients
Biomarkers in CSF can offer improved diagnostic accuracy for Alzheimer’s disease (AD). The present study investigated whether the glycoprotein and putative tumor suppressor Dickkopf homolog 3 (Dkk‐3) is secreted into CSF and evaluated its applicability as a diagnostic marker for AD. Using our highly specific immunoenzymometric assay, Dkk‐3 levels were measured in plasma and/or CSF of patients suffering from depression, mild cognitive impairment (MCI), or AD and compared with healthy subjects. Dkk‐3 identity was verified by western blot and matrix‐assisted laser desorption/ionization time‐of‐flight (MALDI‐TOF) mass spectrometry (MS)/MS. High concentrations of Dkk‐3 were detected in CSF compared with plasma (28.2 ± 1.3 vs. 1.22 ± 0.04 nmol/L, respectively). Consistently Dkk‐3 expression was demonstrated in neurons of the cortex and epithelial cells of the choroid plexus, the major source of CSF. Significantly increased Dkk‐3 levels in plasma and CSF were observed for AD patients compared with healthy subjects but not patients suffering from MCI or depression. In summary, our data indicate that elevated Dkk‐3 levels are specifically associated with AD and might serve as a potential non‐invasive AD biomarker in plasma.
- 25 June 2009
- Published by Wiley in Journal of Neurochemistry
- Vol. 110 (2) , 653-661
Open AccessDkk‐3 is elevated in CSF and plasma of Alzheimer’s disease patients
Biomarkers in CSF can offer improved diagnostic accuracy for Alzheimer’s disease (AD). The present study investigated whether the glycoprotein and putative tumor suppressor Dickkopf homolog 3 (Dkk‐3) is secreted into CSF and evaluated its applicability as a diagnostic marker for AD. Using our highly specific immunoenzymometric assay, Dkk‐3 levels were measured in plasma and/or CSF of patients suffering from depression, mild cognitive impairment (MCI), or AD and compared with healthy subjects. Dkk‐3 identity was verified by western blot and matrix‐assisted laser desorption/ionization time‐of‐flight (MALDI‐TOF) mass spectrometry (MS)/MS. High concentrations of Dkk‐3 were detected in CSF compared with plasma (28.2 ± 1.3 vs. 1.22 ± 0.04 nmol/L, respectively). Consistently Dkk‐3 expression was demonstrated in neurons of the cortex and epithelial cells of the choroid plexus, the major source of CSF. Significantly increased Dkk‐3 levels in plasma and CSF were observed for AD patients compared with healthy subjects but not patients suffering from MCI or depression. In summary, our data indicate that elevated Dkk‐3 levels are specifically associated with AD and might serve as a potential non‐invasive AD biomarker in plasma.
- 19 November 2008
- Published by Taylor & Francis in Expert Opinion on Medical Diagnostics
- Vol. 2 (12) , 1347-1364
Human chorionic gonadotropin isoforms and their epitopes: diagnostic utility in pregnancy and cancer
(2008). Human chorionic gonadotropin isoforms and their epitopes: diagnostic utility in pregnancy and cancer. Expert Opinion on Medical Diagnostics: Vol. 2, No. 12, pp. 1347-1364. doi: 10.1517/17530050802558907
- 19 November 2008
- Published by Taylor & Francis in Expert Opinion on Medical Diagnostics
- Vol. 2 (12) , 1347-1364
Human chorionic gonadotropin isoforms and their epitopes: diagnostic utility in pregnancy and cancer
(2008). Human chorionic gonadotropin isoforms and their epitopes: diagnostic utility in pregnancy and cancer. Expert Opinion on Medical Diagnostics: Vol. 2, No. 12, pp. 1347-1364. doi: 10.1517/17530050802558907
- 1 November 2008
- Published by Elsevier in Experimental Gerontology
- Vol. 43 (11) , 981-985
Aging of the prostate epithelial stem/progenitor cell
- 1 November 2008
- Published by Elsevier in Experimental Gerontology
- Vol. 43 (11) , 981-985
Aging of the prostate epithelial stem/progenitor cell
- 1 July 2008
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 120 (13-14) , 390-401
Pathophysiologie und Therapie der benignen Prostata-Hyperplasie
Benign prostatic hyperplasia (BPH) and benign prostatic enlargement (BPE) are among the most frequent medical disorders of elderly men and cause a number of annoying symptoms of the lower urinary tract (LUTS), leading to reduced quality of life and severe complications, including acute urinary retention. Nodular overgrowth of the epithelium and in particular the fibromuscular tissue is observed in the transition zone and periurethral areas. In particular, functional and phenotypic transdifferentiation of fibroblasts into myofibroblasts is a hallmark of the tissue remodeling in the benign hyperplastic prostate. BPH/BPE have a complex pathophysiology with a multitude of endocrine and local factors involved. Two risk factors, namely aging and circulating androgens, contribute significantly to risk of BPH/BPE. One of the primary initiating mechanisms appears to be a consequence of age-related changes in systemic sex steroid hormone levels accompanied by alterations in local androgen metabolism. This results in the disruption of the delicate balance of interacting growth factor signaling pathways and stromal/epithelial interactions generating a growth promoting and tissue remodeling microenvironment that leads to an increase in prostate volume. Secondarily, altered cytokine and chemoattractant production by the remodeled stroma promotes local inflammation that may further contribute to disease progression via lymphocyte-derived inflammatory cytokines and reactive oxygen/nitrogen species. Local hypoxia as a result of increased oxygen demands of proliferating cells may induce low levels of reactive oxygen species promoting neovascularization and fibroblast-to-myofibroblast transdifferentiation. Medical therapies for LUTS due to BPH/BPE have changed little over the past 15 years with mainstay treatments being α-adrenoreceptor blockade and 5α-reductase inhibitors. We provide an in depth view of the mechanisms underlying BPH/BPE and relate new research findings to the clinical picture with the prospect of novel therapeutic targets, including selective hormone antagonists/agonists, anti-stromal therapy, vitamin-D analogues and approaches to redress the redox imbalance. Die Benigne Prostata Hyperplasie/Vergrößerung (BPH/BPE) ist der häufigste gutartige Tumor des alternden Mannes. Dieser gilt als eine Ursache einer Reihe von Symptomen des unteren Urogenitaltraktes (LUTS, Lower Urinary Tract Symptoms). Die BPH/BPE führt zu Einschränkungen der Lebensqualität sowie zu medizinischen Komplikationen bis hin zur akuten Harnverhaltung. Noduläres Wachstum, vorwiegend des fibromuskulären Gewebes der Transitionszone und der periurethralen Anteile, sowie funktionelle Änderungen der Zellen sind charakteristisch für die beobachtete Gewebsreorganisation in der BPH/BPE. Die Pathophysiologie der BPH/BPE ist komplex und es ist hierbei eine Anzahl endokriner und lokaler Faktoren involviert. Zwei Risikofaktoren sind essentiell für die Entwicklung der BPH/BPE, Altern und Androgene. Einen bedeutenden Einfluss auf die Entstehung scheinen die ab dem 35. Lebensjahr einsetzenden Veränderungen der Sexualsteroidhormon-Serumspiegel und -ratios zu haben. Diese laufen parallel zu Veränderungen im lokalen Sexualsteroidhormon-Stoffwechsel und zu Störungen in Wachstumsfaktor Signaltransduktionswegen in Stroma und Epithel. Das veränderte Stroma fördert über eine veränderte Zytokinproduktion lokale inflammatorische Prozesse, die das Fortschreiten der Erkrankung über inflammatorische Zytokine lymphozytären Ursprungs begünstigen. Lokale Hypoxie, ausgelöst durch zelluläre Proliferation, führt zur Produktion von Sauerstoffradikalen, welche eine Neovaskularisierung und die charaktreristische Transdifferenzierung von Fibroblasten zu glatten Muskelzellen bzw. Myofibroblasten auslösen. Die medikamentösen Standardtherapien von LUTS auf Grund von BPH/BPE haben sich seit 15 Jahren wenig geändert. Es sind dies die Blockade α-adrenerger Rezeptoren und die Hemmung des DHT-konvertierenden Enzyms 5α-Reduktase. In unserer Arbeit fassen wir die vermutlichen molekularen Mechanismen zur Entstehung der BPH/BPE zusammen und zeigen neue Wege zur therapeutischen Intervention auf. Zukünftige Ansätze beinhalten möglicherweise selektive Hormon Antagonisten/Agonisten, anti-stromal Therapie, Vitamin-D Analoga und Substanzen zur Wiederherstellung des Redox Gleichgewichts.
- 1 July 2008
- Published by Springer Nature in Wiener klinische Wochenschrift
- Vol. 120 (13-14) , 390-401
Pathophysiologie und Therapie der benignen Prostata-Hyperplasie
Benign prostatic hyperplasia (BPH) and benign prostatic enlargement (BPE) are among the most frequent medical disorders of elderly men and cause a number of annoying symptoms of the lower urinary tract (LUTS), leading to reduced quality of life and severe complications, including acute urinary retention. Nodular overgrowth of the epithelium and in particular the fibromuscular tissue is observed in the transition zone and periurethral areas. In particular, functional and phenotypic transdifferentiation of fibroblasts into myofibroblasts is a hallmark of the tissue remodeling in the benign hyperplastic prostate. BPH/BPE have a complex pathophysiology with a multitude of endocrine and local factors involved. Two risk factors, namely aging and circulating androgens, contribute significantly to risk of BPH/BPE. One of the primary initiating mechanisms appears to be a consequence of age-related changes in systemic sex steroid hormone levels accompanied by alterations in local androgen metabolism. This results in the disruption of the delicate balance of interacting growth factor signaling pathways and stromal/epithelial interactions generating a growth promoting and tissue remodeling microenvironment that leads to an increase in prostate volume. Secondarily, altered cytokine and chemoattractant production by the remodeled stroma promotes local inflammation that may further contribute to disease progression via lymphocyte-derived inflammatory cytokines and reactive oxygen/nitrogen species. Local hypoxia as a result of increased oxygen demands of proliferating cells may induce low levels of reactive oxygen species promoting neovascularization and fibroblast-to-myofibroblast transdifferentiation. Medical therapies for LUTS due to BPH/BPE have changed little over the past 15 years with mainstay treatments being α-adrenoreceptor blockade and 5α-reductase inhibitors. We provide an in depth view of the mechanisms underlying BPH/BPE and relate new research findings to the clinical picture with the prospect of novel therapeutic targets, including selective hormone antagonists/agonists, anti-stromal therapy, vitamin-D analogues and approaches to redress the redox imbalance. Die Benigne Prostata Hyperplasie/Vergrößerung (BPH/BPE) ist der häufigste gutartige Tumor des alternden Mannes. Dieser gilt als eine Ursache einer Reihe von Symptomen des unteren Urogenitaltraktes (LUTS, Lower Urinary Tract Symptoms). Die BPH/BPE führt zu Einschränkungen der Lebensqualität sowie zu medizinischen Komplikationen bis hin zur akuten Harnverhaltung. Noduläres Wachstum, vorwiegend des fibromuskulären Gewebes der Transitionszone und der periurethralen Anteile, sowie funktionelle Änderungen der Zellen sind charakteristisch für die beobachtete Gewebsreorganisation in der BPH/BPE. Die Pathophysiologie der BPH/BPE ist komplex und es ist hierbei eine Anzahl endokriner und lokaler Faktoren involviert. Zwei Risikofaktoren sind essentiell für die Entwicklung der BPH/BPE, Altern und Androgene. Einen bedeutenden Einfluss auf die Entstehung scheinen die ab dem 35. Lebensjahr einsetzenden Veränderungen der Sexualsteroidhormon-Serumspiegel und -ratios zu haben. Diese laufen parallel zu Veränderungen im lokalen Sexualsteroidhormon-Stoffwechsel und zu Störungen in Wachstumsfaktor Signaltransduktionswegen in Stroma und Epithel. Das veränderte Stroma fördert über eine veränderte Zytokinproduktion lokale inflammatorische Prozesse, die das Fortschreiten der Erkrankung über inflammatorische Zytokine lymphozytären Ursprungs begünstigen. Lokale Hypoxie, ausgelöst durch zelluläre Proliferation, führt zur Produktion von Sauerstoffradikalen, welche eine Neovaskularisierung und die charaktreristische Transdifferenzierung von Fibroblasten zu glatten Muskelzellen bzw. Myofibroblasten auslösen. Die medikamentösen Standardtherapien von LUTS auf Grund von BPH/BPE haben sich seit 15 Jahren wenig geändert. Es sind dies die Blockade α-adrenerger Rezeptoren und die Hemmung des DHT-konvertierenden Enzyms 5α-Reduktase. In unserer Arbeit fassen wir die vermutlichen molekularen Mechanismen zur Entstehung der BPH/BPE zusammen und zeigen neue Wege zur therapeutischen Intervention auf. Zukünftige Ansätze beinhalten möglicherweise selektive Hormon Antagonisten/Agonisten, anti-stromal Therapie, Vitamin-D Analoga und Substanzen zur Wiederherstellung des Redox Gleichgewichts.